WaveMan
WaveMan · Company
IMVT · Immunovant, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IMVT Immunovant (IMVT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001764013
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
113
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $4.8M priced

What the filings say about IMVT

Insiders, 180 days
-$12.8M net sold
8 sellers · 3% of sales under a 10b5-1 plan

Immunovant insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Immunovant, Inc. insiders sold a net $12.8M of stock across 268 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Stout Jay S
Chief Technology Officer
SELL
2026-10-23 SECtraded 2026-10-21
2,595
$75.1K
n/a
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Oct 7, 2026.
  • The trade is 1.3% of the 198,937 shares held after it.
  • 3 other insiders sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Stout Jay S sold about $75.1K of IMVT on Oct 21, 2026; 3 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.
Gloria Melanie
Chief Operating Officer
SELL
2026-10-09 SECtraded 2026-10-07
2,241
$71.8K
-3.6%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Aug 20, 2026.
  • The trade is 1.0% of the 217,060 shares held after it.
  • 3 other insiders sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Gloria Melanie sold about $71.8K of IMVT on Oct 7, 2026; 3 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.
Van Tuyl Christopher
Chief Legal Officer
SELL
2026-10-09 SECtraded 2026-10-07
1,327
$42.5K
-3.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Sep 23, 2026.
  • The trade is 0.8% of the 175,218 shares held after it.
  • 3 other insiders sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Van Tuyl Christopher sold about $42.5K of IMVT on Oct 7, 2026; 3 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.
Stout Jay S
Chief Technology Officer
SELL
2026-10-09 SECtraded 2026-10-07
2,213
$70.9K
-3.6%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Jul 23, 2026.
  • The trade is 1.1% of the 203,128 shares held after it.
  • 3 other insiders sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Stout Jay S sold about $70.9K of IMVT on Oct 7, 2026; 3 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.
Stout Jay S
Chief Technology Officer
SELL
2026-10-09 SECtraded 2026-10-07
1,596
$51.2K
-3.6%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Jul 23, 2026.
  • The trade is 0.8% of the 201,532 shares held after it.
  • 3 other insiders sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Stout Jay S sold about $51.2K of IMVT on Oct 7, 2026; 3 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.
268 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 263 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$12.8M over 180 days
-$734.5K over 90 days
below 86% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
113 funds bought in last quarter
more than 73% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
19.0% of the float short (float per yahoo 2026-10-26) · 9.6 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Oct 23Chief Technology Officer Stout Jay S sold $197.2K (3 trades, Oct 7 to Oct 21)
Oct 9Chief Operating Officer Gloria Melanie sold $71.8K (Oct 7)
Oct 9Chief Legal Officer Van Tuyl Christopher sold $42.5K (Oct 7)
Oct 5Chief Executive Officer Venker Eric sold $119.6K (Oct 2)

Watch IMVT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+50.3%12M
-1%+45%+92%+138%2025-102025-122026-022026-042026-062026-082026-10 2025-12-12 · Roivant Sciences Ltd. bought $350.0M2026-05-28 · Fromkin Andrew J. sold $7.1M2026-06-26 · Stout Jay S sold $1.3M2026-04-23 · Girao Tiago sold $763.0K2026-06-26 · Van Tuyl Christopher sold $572.2K2026-06-26 · Gloria Melanie sold $563.1K2025-12-01 · Fromkin Andrew J. sold $447.8K2026-06-26 · Girao Tiago sold $384.6K2026-05-28 · Fromkin Andrew J. sold $374.8K2026-04-02 · Venker Eric sold $308.2K2025-12-01 · Hughes Douglas J. sold $302.9K2026-07-23 · Girao Tiago sold $263.0K2026-06-26 · Stout Jay S sold $261.8K2025-11-20 · Gloria Melanie sold $241.3K2025-12-18 · Van Tuyl Christopher sold $228.4K2026-04-08 · Gloria Melanie sold $216.6K2026-04-08 · Stout Jay S sold $213.9K2026-05-20 · Pande Atul sold $192.0K2026-08-20 · Gloria Melanie sold $135.0K2026-04-08 · Van Tuyl Christopher sold $128.2K2026-10-02 · Venker Eric sold $119.6K2026-07-02 · Venker Eric sold $119.0K2026-06-26 · Gloria Melanie sold $115.5K2026-06-26 · Van Tuyl Christopher sold $110.7K2026-07-23 · Stout Jay S sold $110.5K2026-09-23 · Van Tuyl Christopher sold $103.5K2026-06-18 · Van Tuyl Christopher sold $93.2K2026-04-23 · Stout Jay S sold $81.6K2026-07-08 · Gloria Melanie sold $76.3K2026-07-08 · Stout Jay S sold $75.3K2026-10-21 · Stout Jay S sold $75.1K2026-10-07 · Gloria Melanie sold $71.8K2026-03-18 · Van Tuyl Christopher sold $71.8K2026-10-07 · Stout Jay S sold $70.9K2025-12-01 · Fromkin Andrew J. sold $69.4K2026-05-01 · Susman Robert Graham sold $68.0K2026-08-28 · Pande Atul sold $64.9K2025-12-18 · Van Tuyl Christopher sold $62.5K2026-07-24 · Pande Atul sold $59.7K2026-06-26 · Pande Atul sold $57.0K2025-11-20 · Gloria Melanie sold $56.9K2026-05-20 · Gloria Melanie sold $55.9K2026-06-26 · TIAGO GIRAO filed to sell $384.6K2026-06-26 · MELANIE GLORIA filed to sell $678.6K2026-06-26 · CHRIS ADAIR VAN TUYL filed to sell $682.8K2026-06-26 · JAY S STOUT filed to sell $1.5M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMVT: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
16,186,469 sh
$623.7M
Deep Track Capital, LP
9,341,151 sh
$359.9M
BlackRock, Inc.
7,180,897 sh
$276.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.
5,805,000 sh
$223.7M
BAKER BROS. ADVISORS LP
5,435,220 sh
$209.4M

Congress trades in IMVT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMVT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
TIAGO GIRAO
Filed 2026-06-26
$384.6K
MELANIE GLORIA
Filed 2026-06-26
$678.6K
CHRIS ADAIR VAN TUYL
Filed 2026-06-26
$682.8K
JAY S STOUT
Filed 2026-06-26
$1.5M

IMVT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global Endurance Portfolio
$789.1K position · as of 2026-06-30
4.9%
Inception Portfolio
$9.7M position · as of 2026-06-30
3.4%
EQ/Morgan Stanley Small Cap Growth Portfolio
$8.1M position · as of 2026-06-30
1.7%
Global X Guru Index ETF
$971.3K position · as of 2026-07-31
1.6%
PGIM Jennison Small-Cap Core Equity Fund
$140.7K position · as of 2026-07-31
1.2%
PGIM Jennison Small Company Fund
$37.8M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Peter Salzmann
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$10.7M
-$9.3M
$4.9M
+7%
-7%
2023
$8.6M
$42.5M
$3.9M
+101%
-4%
2022
$5.8M
$28.2M
$2.0M
-3%
-11%
2021
$5.9M
-$12.3M
$5.6M
-66%
-11%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $12.8M sold by insiders over 180 days, 113 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IMVT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$414.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-80.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-71.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-7.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Net income-$505.6M-$413.8M-$259.3M-$211.0M
EPS (diluted)-2.77-2.73-1.88-1.71
Operating cash flow-$407.3M-$375.9M-$214.2M-$188.2M
Cash$902.1M$714.0M$635.4M$376.5M
SEC XBRL, fiscal years, as known on 2026-10-27

IMVT Stock Sonar score 4/7 axes

Find similar shapesCompare

IMVT ranks highest on institutional and government (73rd percentile) and profitability (36th), and lowest on insider conviction (6th), among Pharma & Biotech peers.

Profitability
36
Inputs
  • Return on equity-80.1% · 39 pct, sector of 545
  • Return on assets-71.1% · 33 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Insider conviction
6
Inputs
  • Net Form 4 buying (codes P and S), 180d-$12.8M · 12 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
73
Inputs
  • Funds adding, latest quarter113 · 73 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+19.0% · 17 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IMVT filings, in plain words

Are Immunovant insiders buying or selling IMVT?

In the 180 days to 2026-10-27, Immunovant insiders were net sellers, a net $12.8M across purchases and sales reported on Form 4, by 8 sellers.

Read the full summary

In the 180 days to 2026-10-27, Immunovant insiders were net sellers of IMVT, a net $12.8M across purchases and sales reported on Form 4 by 8 sellers. 3% of the 38 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies